Vermillion to Present at the 29th Annual Piper Jaffray Healthcare Conference
AUSTIN, Texas, November 20, 2017 — Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that Valerie Palmieri, President and Chief Executive Officer, will provide a corporate overview at the 29th Annual Piper Jaffray Healthcare Conference, being held at the Lotte New York Palace Hotel in New York City on November 28-29, 2017.
Date: Wednesday, November 29
Time: 12:30pm Eastern Time
Location: The Lotte New York Palace Hotel, Track 5, Hubbard 1, 5th Floor
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases. The company’s initial in vitro diagnostic test, OVA1® (MIA), was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016, Vermillion received FDA clearance for Overa™, a Multivariate Index Assay 2nd Generation (MIA2G) test with significantly improved specificity and ease of use. For additional information, including published clinical trials, visit www.vermillion.com.
Investor Relations Contact:
LifeSci Advisors LLC